BidaskClub downgraded shares of Endologix (NASDAQ:ELGX) from a hold rating to a sell rating in a report released on Friday, January 19th.
Several other equities analysts have also commented on the stock. ValuEngine lowered shares of Endologix from a sell rating to a strong sell rating in a report on Sunday, December 31st. JPMorgan Chase & Co. lowered shares of Endologix from a neutral rating to an underweight rating in a report on Tuesday, January 2nd. Royal Bank of Canada decreased their target price on shares of Endologix from $5.00 to $4.00 and set a sector perform rating on the stock in a report on Wednesday, November 8th. Stifel Nicolaus set a $6.00 target price on shares of Endologix and gave the company a hold rating in a report on Friday, October 6th. Finally, Piper Jaffray Companies reissued an overweight rating on shares of Endologix in a report on Tuesday, December 12th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. Endologix presently has a consensus rating of Hold and a consensus price target of $5.41.
Shares of Endologix (NASDAQ:ELGX) traded down $0.25 during trading on Friday, reaching $3.79. 4,060,230 shares of the company’s stock traded hands, compared to its average volume of 765,101. Endologix has a twelve month low of $3.77 and a twelve month high of $7.66. The company has a quick ratio of 2.11, a current ratio of 2.90 and a debt-to-equity ratio of 2.61. The firm has a market cap of $351.34, a PE ratio of -4.34 and a beta of 0.42.
Several institutional investors have recently made changes to their positions in the stock. ArrowMark Colorado Holdings LLC grew its holdings in shares of Endologix by 11.8% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 9,890,106 shares of the medical instruments supplier’s stock valued at $52,912,000 after purchasing an additional 1,043,986 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Endologix by 5.6% during the 2nd quarter. Vanguard Group Inc. now owns 6,638,302 shares of the medical instruments supplier’s stock valued at $32,262,000 after purchasing an additional 353,233 shares during the last quarter. Redmile Group LLC grew its holdings in shares of Endologix by 134.4% during the 2nd quarter. Redmile Group LLC now owns 6,368,299 shares of the medical instruments supplier’s stock valued at $30,950,000 after purchasing an additional 3,650,905 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Endologix by 1.1% during the 4th quarter. BlackRock Inc. now owns 5,093,047 shares of the medical instruments supplier’s stock valued at $27,248,000 after purchasing an additional 56,745 shares during the last quarter. Finally, Senzar Asset Management LLC grew its holdings in shares of Endologix by 143.6% during the 4th quarter. Senzar Asset Management LLC now owns 2,196,225 shares of the medical instruments supplier’s stock valued at $11,750,000 after purchasing an additional 1,294,684 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/14/endologix-elgx-rating-lowered-to-sell-at-bidaskclub.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.